GLACIER: An open-label, randomized, multicenter study to assess the safety and tolerability of glatiramer acetate [amount hidden] three-times weekly versus [amount hidden] daily in patients with relapsing-remitting multiple sclerosis

What Was Tested

The paper reports a study of Glatiramer Acetate in the context of multiple sclerosis, published as a randomized controlled trial.

To evaluate the safety, tolerability, and patient experience when converting from GA20 to GA40.

Why It Was Studied

However, injection-related adverse events (IRAEs) may impede treatment adherence and tolerability.

Who Took Part

PubMed indexes the participants as middle-aged adults, both men and women.

Stable RRMS patients on GA20 were randomized in a 1:1 ratio to continue with GA20 or convert to GA40.

Additionally, the severity of IRAEs, rate of injection-site reactions (ISRs), and patient-reported MS impact and treatment satisfaction were compared for the two treatment groups over the 4-month core study.

How the Study Was Run

The design is described as randomized, open-label and parallel-group.

Random assignment meant chance, not the researchers, decided who got Glatiramer Acetate and who got the comparison, which limits bias.

Everyone knew when Glatiramer Acetate was being given (open label), which is simpler to run but leaves more room for expectations to affect what is reported.

Groups ran in parallel: each of the participants stayed in one arm throughout.

GLACIER was an open-label, randomized, parallel-group trial conducted at 31 sites in the US between June 2013 and December 2013.

The adjusted mean annualized rate of IRAEs was the primary endpoint for this study.

What Was Measured

PubMed files the paper under topics including Cohort Studies, Disability Evaluation, Glatiramer Acetate, Immunosuppressive Agents, Multiple Sclerosis, Relapsing-Remitting, Patient Satisfaction and United States.

The authors tagged it with the keywords Convenience, Patient adherence, Relapsing-remitting multiple sclerosis and Safety.

What This Means in Plain Language

The paper is a randomized, open-label and parallel-group study of Glatiramer Acetate in people with multiple sclerosis.

Its findings take up roughly 5 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2015 (Multiple sclerosis and related disorders), a journal based in Netherlands.

More context: the Glatiramer Acetate compound page, Multiple sclerosis research.